Flecainide/Modafinil - Theranexus

Drug Profile

Flecainide/Modafinil - Theranexus

Alternative Names: Modafinil/ THN02; Modafinil/flecainide - Theranexus; THN-102

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Theranexus
  • Class Benzhydryl compounds; Class Ic antiarrhythmics; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Narcolepsy

Most Recent Events

  • 27 Oct 2016 Phase-II clinical trials in Narcolepsy in France (PO) , NCT02821715)
  • 04 Oct 2016 Flecainide/Modafinil - Theranexus receives Orphan Drug status for Narcolepsy in USA
  • 30 Mar 2016 Theranexus completes a phase I safety trial in Narcolepsy in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top